Given that novel targeted therapies are being developed in ER+ breast cancer, changes in the biology of the tumor that occur during adjuvant therapy could adversely impact predictive value of diagnostic assessments conducted on primary tumor samples but used to guide therapy in metastatic patients. The gene discussed is ESR1; the disease is breast carcinoma.